Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies

Autor:	Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, Gruca D, Norton M
Jazyk:	angličtina
Rok vydání:	2016
Předmět:	androgen deprivation therapy gonadotropin-releasing hormone analog prostate cancer castrate levels Diseases of the genitourinary system. Urology RC870-923
Zdroj:	Research and Reports in Urology, Vol Volume 8, Pp 159-164 (2016)
Druh dokumentu:	article
ISSN:	2253-2447
Popis:	Aaron Spitz,1 Marc Gittelman,2 Lawrence I Karsh,3 Sanja Dragnic,4 Ahmed M Soliman,5 Aditya Lele,6 Damian Gruca,7 Michael Norton4 1Orange County Urology Associates, Laguna Beach, CA, 221st Century Oncology/UroMedix-Aventura Division, Aventura, FL, 3The Urology Center of Colorado, Denver, CO, 4US Medical Affairs, 5Health Economics and Outcomes Research, 6Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA; 7Global Medical Affairs, AbbVie Deutschland, Ludwigshafen, Germany Introduction: Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) analogs is a standard treatment for advanced prostate cancer. GnRH analog therapy can reduce testosterone to “castrate” levels, historically defined as
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/0e23c9485fa54ed0b7d4e39b729e616f Zobrazit plný text záznamu View record in DOAJ